Jaguar Health Announces Completed Analysis From Phase 3 OnTarget Trial

TipRanksOct 1 08:55 ET

Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in Its Phase 3 OnTarget Trial for Its Cancer Supportive Care Drug Crofelemer

AccesswireOct 1 08:30 ET

Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patients...

AccesswireSep 26 10:00 ET

Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch

AccesswireSep 24 10:00 ET

Jaguar Health Appoints Industry Veteran to Head Sales for Company's Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care

AccesswireSep 10 10:00 ET

Jaguar Health to Present at the September 9-11 H.C. Wainwright Annual Global Investment Conference

AccesswireSep 6 10:00 ET